Data as of Sep 19
| +0.09 / +0.48%|
The 6 analysts offering 12-month price forecasts for Theravance Inc have a median target of 27.50, with a high estimate of 47.00 and a low estimate of 7.00. The median estimate represents a +46.90% increase from the last price of 18.72.
The current consensus among 7 polled investment analysts is to Hold stock in Theravance Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.